Cystatin C ELISA Kit, Human

Temporarily not available outside of China.

Cystatin C ELISA Kit, Human: 产品信息

Cystatin C ELISA Kit, Human
Solid Phase Sandwich ELISA (quantitative)
Serum,Cell supernatant,Urine
1.54 pg/mL
3.91-250 pg/mL
Recognizes both recombinant and natural Human Cystatin C
  Intra-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 58.00 107.00 204.00
SD 1.51 2.19 3.61
CV(%) 2.6% 2.0% 1.8%
  Inter-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 49.00 97.00 190.00
SD 6.77 8.07 18.84
CV(%) 13.9% 8.3% 9.9%
The recovery of Human CST3 spiked to different levels throughout the range of the assay in related matrices was evaluated.
serum (n=3)
Average % Recovery
94 -106%
supernatant (n=3)
Average % Recovery
99 -111%
urine (n=3)
Average % Recovery
93 -106%
  Recovery of detected
1:2 99%
1:4 99%
1:8 102%
1:16 90%
  Recovery of detected
1:2 105%
1:4 97%
1:8 101%
1:16 88%
  Recovery of detected
1:2 83%
1:4 98%
1:8 102%
1:16 84%
ELISA 试剂盒(即用型)组分
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
This Cystatin C ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human Cystatin C protein in Serum,Cell supernatant,Urine . It contains recombinant Human Cystatin C, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
This ELISA Kit is shipped at ambient temperature.
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA

Cystatin C ELISA Kit, Human: 图片

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
This assay recognizes both recombinant and natural Human CST3. The factors listed below were prepared at 50 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.

Cystatin C ELISA Kit, Human: 别称

ARMD11 ELISA Kit, Human

Cystatin C 背景信息

Cystatin C, also known as Cystatin-3 (CST3) is a secreted type 2 cysteine protease inhibitor synthesized in all nucleated cells, has been proposed as a replacement for serum creatinine for the assessment of renal function, particularly to detect small reductions in glomerular filtration rate. The mature, active form of human cystatin C is a single non-glycosylated polypeptide chain consisting of 12 amino acid residues, with a molecular mass of 13,343-13,359 Da, and containing four characteristic disulfide-paired cysteine residues. Cystatin C is a low-molecular-weight protein which has been proposed as a marker of renal function that could replace creatinine. Indeed, the concentration of Cystatin C is mainly determined by glomerular filtration and is particularly of interest in clinical settings where the relationship between creatinine production and muscle mass impairs the clinical performance of creatinine. Since the last decade, numerous studies have evaluated its potential use in measuring renal function in various populations. More recently, other potential developments for its clinical use have emerged. In almost all the clinical studies, Cystatin C demonstrated a better diagnostic accuracy than serum creatinine in discriminating normal from impaired kidney function, but controversial results have been obtained by comparing this protein with other indices of kidney disease, especially serum creatinine-based equations, such as early atherosclerosis, Alzheimer's dementia, vascular aneurysms, hyperhomocysteinaemia and other neurodegenerative diseases. Cystatin C could be a useful clinical tool to identify HIV-infected persons. In addition, its expression is up-regulated in malignance of certain tumor progression.
cystatin C
  • Mares J, et al. (2003) Use of cystatin C determination in clinical diagnostics. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 147(2): 177-80.
  • Mussap M, et al. (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 41(5-6): 467-550.
  • Sronie-Vivien S, et al. (2008) Cystatin C: current position and future prospects. Clin Chem Lab Med. 46(12): 1664-86.
  • Taglieri N, et al. (2009) Cystatin C and cardiovascular risk. Clin Chem. 55(11): 1932-43.
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.